Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Liabilities (2017 - 2022)

Historic Total Liabilities for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to $538.0 million.

  • Arcus Biosciences' Total Liabilities fell 2680.27% to $538.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $538.0 million, marking a year-over-year decrease of 2680.27%. This contributed to the annual value of $665.0 million for FY2024, which is 505.53% up from last year.
  • According to the latest figures from Q3 2025, Arcus Biosciences' Total Liabilities is $538.0 million, which was down 2680.27% from $526.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Total Liabilities registered a high of $750.4 million during Q4 2021, and its lowest value of $270.3 million during Q1 2021.
  • In the last 5 years, Arcus Biosciences' Total Liabilities had a median value of $643.0 million in 2022 and averaged $593.9 million.
  • In the last 5 years, Arcus Biosciences' Total Liabilities surged by 66136.15% in 2021 and then plummeted by 2680.27% in 2025.
  • Quarter analysis of 5 years shows Arcus Biosciences' Total Liabilities stood at $750.4 million in 2021, then fell by 14.32% to $643.0 million in 2022, then dropped by 1.56% to $633.0 million in 2023, then grew by 5.06% to $665.0 million in 2024, then fell by 19.1% to $538.0 million in 2025.
  • Its last three reported values are $538.0 million in Q3 2025, $526.0 million for Q2 2025, and $625.0 million during Q1 2025.